sur Moderna, Inc. (NASDAQ:MRNA)
Moderna Secures $176 Million for mRNA-Based Influenza Vaccine Development
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) has announced a $176 million award through the Rapid Response Partnership Vehicle (RRPV) to expedite the development of mRNA-based pandemic influenza vaccines. This funding, provided by the Biomedical Advanced Research and Development Authority (BARDA), aims to support the late-stage development of a pre-pandemic H5 influenza virus vaccine.
The H5 influenza virus, known for causing severe disease in birds, poses a threat of human transmission. Moderna's project includes further options to prepare and respond to future public health challenges. CEO Stéphane Bancel highlighted the advantages of mRNA technology in addressing infectious diseases, as evidenced during the COVID-19 pandemic.
In 2023, Moderna initiated a Phase 1/2 study to assess the safety and immunogenicity of its mRNA-1018 influenza vaccine in adults. Results are expected in 2024 and will guide Phase 3 plans. This project is federally funded under Other Transaction (OT) number: 75A50123D00005.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Moderna, Inc.